Patent ID: 7658926
Filing Date: 2010-02-09
Classification: A61K,A61P,C12N

Abstract:
1. An autologous T cell vaccine for the treatment of multiple sclerosis made by a process comprising: (a) obtaining a plurality of mononuclear cells comprising T cells from a patient to be treated with the vaccine; (b) incubating the T cells in the presence of a human multiple sclerosis associated antigen; (c) stimulating the T cells obtained in step b) with antigen presenting cells APC(s) and the multiple sclerosis associated antigen; (d) stimulating the T cells of step c) with the multiple sclerosis associated antigen; (e) stimulating the T cells of step d) with a mitogen in the presence of IL-2; (f) repeating steps d) and e) one or more times; and (g) irradiating the T cells, wherein the multiple sclerosis antigen consists of amino acids 83-99 of myelin basic protein and amino acids 151-170 of myelin basic protein.